Since 2000, when Reolysin first entered the clinic, Oncolytics has enrolled some 330 patients in multiple Phase 1 and 2 studies. “When we lump all indications together, you see this pattern, where people have a three-in-four chance of stabilizing or having a tumour regress fairly significantly. And an even higher percentage in metastatic lesions,” he adds.
Is this guy serious? Lump all indications together? lol, that's a joke. Whatever happened to doing several complete and proper trials to see the benefits. It seems to me that these guys are trying to cut corners and jumping into Phase III.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.